APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cytomegalovirus (CMV) Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cytomegalovirus (CMV) Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025175 pages

Choose your research edition.

Industry ResearchCytomegalovirus (CMV) Vaccine Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Cytomegalovirus (CMV) Vaccine Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Cytomegalovirus (CMV) Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cytomegalovirus (CMV) Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cytomegalovirus (CMV) Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Cytomegalovirus (CMV) Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cytomegalovirus (CMV) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cytomegalovirus (CMV) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cytomegalovirus (CMV) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cytomegalovirus (CMV) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cytomegalovirus (CMV) Vaccine include AlphaVax, Moderna, Merck and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cytomegalovirus (CMV) Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cytomegalovirus (CMV) Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cytomegalovirus (CMV) Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cytomegalovirus (CMV) Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Cytomegalovirus (CMV) Vaccine Segment by Company

AlphaVax

Moderna

Merck

Novartis

Cytomegalovirus (CMV) Vaccine Segment by Type

Attenuated Vaccines

Subunit Vaccines

Cytomegalovirus (CMV) Vaccine Segment by Application

Laboratories

Hospitals

Diagnostic Centers and Clinics

Others

Cytomegalovirus (CMV) Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cytomegalovirus (CMV) Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cytomegalovirus (CMV) Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cytomegalovirus (CMV) Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cytomegalovirus (CMV) Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cytomegalovirus (CMV) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cytomegalovirus (CMV) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cytomegalovirus (CMV) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cytomegalovirus (CMV) Vaccine Industry Trends Table 2. Cytomegalovirus (CMV) Vaccine Industry Drivers Table 3. Cytomegalovirus (CMV) Vaccine Industry Opportunities and Challenges Table 4. Cytomegalovirus (CMV) Vaccine Industry Restraints Table 5. Global Cytomegalovirus (CMV) Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cytomegalovirus (CMV) Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Manufacturers Table 9. Global Cytomegalovirus (CMV) Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Cytomegalovirus (CMV) Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cytomegalovirus (CMV) Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cytomegalovirus (CMV) Vaccine Manufacturers, Product Type & Application Table 13. Global Cytomegalovirus (CMV) Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cytomegalovirus (CMV) Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Attenuated Vaccines Table 17. Major Manufacturers of Subunit Vaccines Table 18. Global Cytomegalovirus (CMV) Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Cytomegalovirus (CMV) Vaccine Sales by Type (2021-2026) & (K Units) Table 20. Global Cytomegalovirus (CMV) Vaccine Sales by Type (2027-2032) & (K Units) Table 21. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Cytomegalovirus (CMV) Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Cytomegalovirus (CMV) Vaccine Revenue by Type (2021-2026) & (K Units) Table 25. Global Cytomegalovirus (CMV) Vaccine Revenue by Type (2027-2032) & (K Units) Table 26. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Laboratories Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Diagnostic Centers and Clinics Table 31. Major Manufacturers of Others Table 32. Global Cytomegalovirus (CMV) Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Cytomegalovirus (CMV) Vaccine Sales by Application (2021-2026) & (K Units) Table 34. Global Cytomegalovirus (CMV) Vaccine Sales by Application (2027-2032) & (K Units) Table 35. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Application (2021-2026) Table 36. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Application (2027-2032) Table 37. Global Cytomegalovirus (CMV) Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Cytomegalovirus (CMV) Vaccine Revenue by Application (2021-2026) & (K Units) Table 39. Global Cytomegalovirus (CMV) Vaccine Revenue by Application (2027-2032) & (K Units) Table 40. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Application (2021-2026) Table 41. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Application (2027-2032) Table 42. Global Cytomegalovirus (CMV) Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Cytomegalovirus (CMV) Vaccine Sales by Region (2021-2026) & (K Units) Table 44. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Cytomegalovirus (CMV) Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Cytomegalovirus (CMV) Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Cytomegalovirus (CMV) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2026) & (K Units) Table 49. North America Cytomegalovirus (CMV) Vaccine Sales by Country (2027-2032) & (K Units) Table 50. Europe Cytomegalovirus (CMV) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2026) & (K Units) Table 52. Europe Cytomegalovirus (CMV) Vaccine Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Cytomegalovirus (CMV) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Cytomegalovirus (CMV) Vaccine Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales by Country (2027-2032) & (K Units) Table 59. Global Cytomegalovirus (CMV) Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Cytomegalovirus (CMV) Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Cytomegalovirus (CMV) Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Region (2021-2026) Table 63. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Region (2027-2032) Table 64. AlphaVax Company Information Table 65. AlphaVax Business Overview Table 66. AlphaVax Cytomegalovirus (CMV) Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. AlphaVax Cytomegalovirus (CMV) Vaccine Product Portfolio Table 68. AlphaVax Recent Development Table 69. Moderna Company Information Table 70. Moderna Business Overview Table 71. Moderna Cytomegalovirus (CMV) Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Moderna Cytomegalovirus (CMV) Vaccine Product Portfolio Table 73. Moderna Recent Development Table 74. Merck Company Information Table 75. Merck Business Overview Table 76. Merck Cytomegalovirus (CMV) Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Merck Cytomegalovirus (CMV) Vaccine Product Portfolio Table 78. Merck Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis Cytomegalovirus (CMV) Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Novartis Cytomegalovirus (CMV) Vaccine Product Portfolio Table 83. Novartis Recent Development Table 84. Key Raw Materials Table 85. Raw Materials Key Suppliers Table 86. Cytomegalovirus (CMV) Vaccine Distributors List Table 87. Cytomegalovirus (CMV) Vaccine Customers List Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Cytomegalovirus (CMV) Vaccine Product Image Figure 2. Global Cytomegalovirus (CMV) Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cytomegalovirus (CMV) Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Cytomegalovirus (CMV) Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Cytomegalovirus (CMV) Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cytomegalovirus (CMV) Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Attenuated Vaccines Image Figure 9. Subunit Vaccines Image Figure 10. Global Cytomegalovirus (CMV) Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Cytomegalovirus (CMV) Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Cytomegalovirus (CMV) Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Laboratories Image Figure 17. Hospitals Image Figure 18. Diagnostic Centers and Clinics Image Figure 19. Others Image Figure 20. Global Cytomegalovirus (CMV) Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Cytomegalovirus (CMV) Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Application (2021-2032) Figure 23. Global Cytomegalovirus (CMV) Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Application (2021-2032) Figure 26. North America Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Cytomegalovirus (CMV) Vaccine Sales Market Share by Country (2021-2032) Figure 28. U.S. Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Cytomegalovirus (CMV) Vaccine Sales Market Share by Country (2021-2032) Figure 33. Germany Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Cytomegalovirus (CMV) Vaccine Sales Market Share by Country (2021-2032) Figure 40. China Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales Market Share by Country (2021-2032) Figure 48. Brazil Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Cytomegalovirus (CMV) Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Cytomegalovirus (CMV) Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Cytomegalovirus (CMV) Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. North America Cytomegalovirus (CMV) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Cytomegalovirus (CMV) Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Europe Cytomegalovirus (CMV) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Cytomegalovirus (CMV) Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Cytomegalovirus (CMV) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Cytomegalovirus (CMV) Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Cytomegalovirus (CMV) Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Attenuated Vaccines
  • Subunit Vaccines
Applications
  • Laboratories
  • Hospitals
  • Diagnostic Centers and Clinics
  • Others
Companies covered
  • AlphaVax
  • Moderna
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cytomegalovirus (CMV) Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cytomegalovirus (CMV) Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cytomegalovirus (CMV) Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cytomegalovirus (CMV) Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cytomegalovirus (CMV) Vaccine Market Dynamics
  1. 2.1 Cytomegalovirus (CMV) Vaccine Industry Trends
  2. 2.2 Cytomegalovirus (CMV) Vaccine Industry Drivers
  3. 2.3 Cytomegalovirus (CMV) Vaccine Industry Opportunities and Challenges
  4. 2.4 Cytomegalovirus (CMV) Vaccine Industry Restraints
3 Cytomegalovirus (CMV) Vaccine Market by Manufacturers
  1. 3.1 Global Cytomegalovirus (CMV) Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cytomegalovirus (CMV) Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cytomegalovirus (CMV) Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cytomegalovirus (CMV) Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cytomegalovirus (CMV) Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cytomegalovirus (CMV) Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Cytomegalovirus (CMV) Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cytomegalovirus (CMV) Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cytomegalovirus (CMV) Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cytomegalovirus (CMV) Vaccine Tier 1, Tier 2, and Tier 3
4 Cytomegalovirus (CMV) Vaccine Market by Type
  1. 4.1 Cytomegalovirus (CMV) Vaccine Type Introduction
  2. 4.1.1 Attenuated Vaccines
  3. 4.1.2 Subunit Vaccines
  4. 4.2 Global Cytomegalovirus (CMV) Vaccine Sales by Type
  5. 4.2.1 Global Cytomegalovirus (CMV) Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cytomegalovirus (CMV) Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Cytomegalovirus (CMV) Vaccine Revenue by Type
  9. 4.3.1 Global Cytomegalovirus (CMV) Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Cytomegalovirus (CMV) Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Type (2021-2032)
5 Cytomegalovirus (CMV) Vaccine Market by Application
  1. 5.1 Cytomegalovirus (CMV) Vaccine Application Introduction
  2. 5.1.1 Laboratories
  3. 5.1.2 Hospitals
  4. 5.1.3 Diagnostic Centers and Clinics
  5. 5.1.4 Others
  6. 5.2 Global Cytomegalovirus (CMV) Vaccine Sales by Application
  7. 5.2.1 Global Cytomegalovirus (CMV) Vaccine Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Cytomegalovirus (CMV) Vaccine Sales by Application (2021-2032)
  9. 5.2.3 Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Application (2021-2032)
  10. 5.3 Global Cytomegalovirus (CMV) Vaccine Revenue by Application
  11. 5.3.1 Global Cytomegalovirus (CMV) Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Cytomegalovirus (CMV) Vaccine Revenue by Application (2021-2032)
  13. 5.3.3 Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Application (2021-2032)
6 Global Cytomegalovirus (CMV) Vaccine Sales by Region
  1. 6.1 Global Cytomegalovirus (CMV) Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cytomegalovirus (CMV) Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Cytomegalovirus (CMV) Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Cytomegalovirus (CMV) Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cytomegalovirus (CMV) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cytomegalovirus (CMV) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cytomegalovirus (CMV) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cytomegalovirus (CMV) Vaccine Revenue by Region
  1. 7.1 Global Cytomegalovirus (CMV) Vaccine Revenue by Region
  2. 7.1.1 Global Cytomegalovirus (CMV) Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cytomegalovirus (CMV) Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Cytomegalovirus (CMV) Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cytomegalovirus (CMV) Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Cytomegalovirus (CMV) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cytomegalovirus (CMV) Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Cytomegalovirus (CMV) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cytomegalovirus (CMV) Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cytomegalovirus (CMV) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cytomegalovirus (CMV) Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AlphaVax
  2. 8.1.1 AlphaVax Company Information
  3. 8.1.2 AlphaVax Business Overview
  4. 8.1.3 AlphaVax Cytomegalovirus (CMV) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AlphaVax Cytomegalovirus (CMV) Vaccine Product Portfolio
  6. 8.1.5 AlphaVax Recent Developments
  7. 8.2 Moderna
  8. 8.2.1 Moderna Company Information
  9. 8.2.2 Moderna Business Overview
  10. 8.2.3 Moderna Cytomegalovirus (CMV) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Moderna Cytomegalovirus (CMV) Vaccine Product Portfolio
  12. 8.2.5 Moderna Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Cytomegalovirus (CMV) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Cytomegalovirus (CMV) Vaccine Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Cytomegalovirus (CMV) Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Cytomegalovirus (CMV) Vaccine Product Portfolio
  24. 8.4.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cytomegalovirus (CMV) Vaccine Value Chain Analysis
  2. 9.1.1 Cytomegalovirus (CMV) Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cytomegalovirus (CMV) Vaccine Production Mode & Process
  6. 9.2 Cytomegalovirus (CMV) Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cytomegalovirus (CMV) Vaccine Distributors
  9. 9.2.3 Cytomegalovirus (CMV) Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst